{"nctId":"NCT04380519","briefTitle":"Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)","startDateStruct":{"date":"2020-04-23","type":"ACTUAL"},"conditions":["COVID-19"],"count":372,"armGroups":[{"label":"RPH -104 80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: RPH-104 80 mg"]},{"label":"Olokizumab 64 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Olokizumab 64 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"RPH-104 80 mg","otherNames":[]},{"name":"Olokizumab 64 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. The presence of a voluntarily signed and dated Patient Informed Consent Form for participation in this study, or a record of an Medical Consilium decision justifying patient's participation in case of patient is unable to state his/her will.\n2. Having either of the following COVID-associated respiratory syndromes:\n\n   * pneumonia with oxygenation saturation SpO2 ≤93% (on room air) or respiratory rate greater than 30/min;\n   * Acute respiratory distress syndrome (ARDS) ( PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315 if PaO2 is not available).\n3. COVID-19 diagnosis based on:\n\n   * laboratory-confirmed SARS-CoV-2 infection as determined by Polymerase Chain Reaction method (PCR).\n\nOR\n\n• Bilateral changes in the lungs typical for COVID-19, based on chest computed tomography results.\n\nExclusion criteria:\n\n1. A history of hypersensitivity to the study drugs (RPH-104 and/or OKZ), and/or their components.\n2. The presence of any of the following laboratory abnormalities:\n\n   * absolute neutrophil counts \\< 0.5 x 10\\^9 L\n   * white blood cell count \\< 2 x 10\\^9 L\n   * platelet count \\<50 x 10\\^9 L\n   * Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) ≥ 3.0 x Upper Limit of Normal (ULN)\n3. Severe renal failure: creatinine clearance \\< 30 mL/min\n4. Septic shock (vasopressors are required to maintain mean arterial pressure ≥ 65 mm Hg and lactate ≥ 2 mmol/L in the absence of hypovolemia)\n5. The disease progresses to death over the next 24 hours, regardless of treatment, according to Investigator.\n6. Perforation of the gastrointestinal tract, a history of diverticulitis.\n7. Administration of plasma from COVID-19 convalescent donors within 4 weeks before study enrollment and/or planned administration during the study.\n8. Recent (less then 5 half-lives) administration of tocilizumab or sarilumab;\n9. Recent (less then 5 half-lives) or planned during the current study period use of the following drugs:\n\n   * biologics (except RPH-104 or OKZ) with immunosuppressive effect, including, but not limited to: Interleukin-1 (IL-1) inhibitors (anakinra, rilonacept, canakinumab), IL- 6 inhibitors (except tocilizumab and sarilumab), IL-17A inhibitors (secukinumab), tumor necrosis factor α (TNFα) inhibitors (infliximab, adalimumab, etanercept, etc.), antiB-cell drugs, etc.\n   * other immunosuppressive drugs (with the exception of methotrexate in a dose of up to 25 mg/week), including, but not limited to:\n\n     1. high doses of glucocorticoids (equivalent to prednisolone \\> 1 mg/kg) orally or parenterally;\n     2. Janus kinase (JAK) kinase inhibitors; cyclophosphamide, etc.\n10. Concurrent participation in another clinical trial.\n11. Pregnancy, breastfeeding.\n12. A history of active tuberculosis, or active tuberculosis suspected by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Responders in Each Treatment Group","description":"Proportion of patients, responded to the study therapy, in each of the treatment groups.\n\nA responder is a patient who has not received tocilizumab or sarilumab and who has a clinical status improvement of ≥1 point on the 6-point COVID-19 scale (where 1 is the most favorable outcome and 6 is the most undesirable outcome) 15 days after the administration of the study drug:\n\n1. Not hospitalized, no activity limitations.\n2. Not hospitalized, limited activity.\n3. Hospitalized, not requiring supplemental oxygen.\n4. Hospitalized, supplemental oxygen with independent breathing.\n5. Hospitalized; mechanical ventilation (invasive/non-invasive) or Extracorporeal membrane oxygenation (ECMO).\n6. Death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Change Over Time in the Clinical Status of Patients Using a 6-point Ordinal Scale","description":"Changes of patients' clinical status on a 6 points ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) over time.\n\nThe 6-point ordinal scale included the following categories:\n\n1. Not hospitalized, no activity limitations.\n2. Not hospitalized, limited activity.\n3. Hospitalized, not requiring supplemental oxygen.\n4. Hospitalized, supplemental oxygen, with independent breathing.\n5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.\n6. Death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"96","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"111","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients With an Improvement in Clinical Status by 2 or More Points on the 6-point Ordinal Scale During the Study With no Use of Tocilizumab or Sarilumab","description":"The proportion of patients with an improvement in clinical status by 2 or more points on the 6-point ordinal scale (where 1 was the most favorable outcome and 6 was the most undesirable outcome) during the study with no use of tocilizumab or sarilumab.\n\nThe 6-point ordinal scale included the following categories:\n\n1. Not hospitalized, no activity limitations.\n2. Not hospitalized, limited activity.\n3. Hospitalized, not requiring supplemental oxygen.\n4. Hospitalized, supplemental oxygen, with independent breathing.\n5. Hospitalized, mechanical ventilation (invasive/non-invasive) or ECMO.\n6. Death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients Who Received Tocilizumab or Sarilumab for COVID-19 During the Study","description":"The proportion of patients who received tocilizumab or sarilumab for COVID-19 during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Rate During the Study","description":"Mortality rate over the follow-up period of the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":123},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Gamma-glutamyltransferase increased"]}}}